REQUEST FOR SUPPORT

KAUAI, HI, USA • 8-12 DECEMBER 2019
Dear Colleague,

The focus of HEP DART is to assemble clinicians, medical professionals, nurses, researchers and basic scientists together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis, NASH, and co-infections.

HEP DART 2019 will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in hepatology (including viral hepatitis, NASH, and co-infections). Key points of the meeting will be basic science and clinical medicine.

The program includes plenary lectures, abstract and poster presentations, along with discussion & debate. There will be plenty of time for Q&A in the panel discussions scheduled at the end of each session and more than enough occasions to unwind, relax and socialize with your colleagues!

Kind regards,
The 2019 Meeting Chairs
COMMITTEES

WORLD’S LEADING EXPERTS

The HEP DART series proudly collaborates with a large number of international experts in the field of Hepatitis. By working together with our extensive global network of experts from various backgrounds in the field we can ensure to design and deliver the most relevant and state-of-the-art program.

ORGANIZING COMMITTEE

The members of the Organizing Committee (OC) are carefully selected experts and inspirational leaders in their respective fields. They come together on a frequent basis to develop the scientific program tailored to the needs of Healthcare professionals in the field. Furthermore, they identify clinical studies and research projects within their organizations/ network and review and select abstracts. They actively participate as session chairs and join the Q&A sessions, discussions and debates during the meeting.

Raymond Schinazi
PhD, DSc
Emory University
United States

Charles Boucher
MD, PhD
Erasmus Medical Center
The Netherlands

Charles M. Rice
PhD
The Rockefeller University
United States

Eugene R. Schiff
MD
University of Miami
United States

Mark Sulkowski
MD
Johns Hopkins University
United States
SCIENTIFIC COMMITTEE
The members of the Scientific Committee (SC) are hand-picked by the OC and the conference secretariat based on their significant contributions and commitment to the field. They assist the OC by providing them with topic and speaker suggestions. In addition, members of the SC participate in reviewing submitted abstracts, and play an active role during the workshop.

- Harvey Alter, MD - National Institutes of Health, USA
- Ralf Bartenschlager, PhD - University of Heidelberg, Germany
- Adrian Di Bisceglie, MD - Saint Louis University, USA
- Geoffrey Dusheiko, MD, MB, BCh - University College London, UK
- Michael Fried, MD - University of North Carolina, USA
- Robert Gish, MD - Robert G. Gish Consultants, LLC, USA
- Jason Grebely, BSc, PhD - University of New South Wales, Australia
- Brent Korba, PhD - Georgetown University, USA
- Shyamasundaran Kottilil, MD - University of Maryland, USA
- George Lau, MD, MBBS, MRCP - Humanity and Health Liver Clinic, Hong Kong
- Stanley Lemon, MD - University of North Carolina, at Chapel Hill, USA
- Stephen Locarnini, MD, PhD - Victorian Infectious Diseases Reference Laboratory, Australia
- Anna Lok, MD - University of Michigan Medical Center, USA
- Michael Manns, MD - Hannover Medical School, Germany
- Patrick Marcellin, MD, PhD - Beaumoin Hospital, France
- John McHutchison, MD - Gilead Sciences, Inc., USA
- Marion Peters, MD - University of California, San Francisco, USA
NEEDS ASSESSMENT

Viral hepatitis is a problem of enormous proportions around the world. It is estimated that over 300 million people are persistently infected; many of who will develop associated liver pathologies such as chronic hepatic insufficiency, cirrhosis, and hepatocellular carcinoma. Alarmingly, mortality rates are on the rise, in 2015 the disease caused 1.34 million deaths. Hence, there is a need to increase efforts to stop this trend.

Even though we have effective means to control hepatitis B and recent advances in drug development are making it technically possible to cure hepatitis C, many countries are struggling to control infections and viral hepatitis remains a major public health threat. It is therefore important to increase efforts to limit transmission, increase access to treatment, and educate the medical community about the current guidelines and treatment options for viral hepatitis. It is also critical to keep abreast of new drug developments to facilitate the development of novel and potent therapies for viral hepatitis. It is vital that clinicians and researchers come together to discuss current and future challenges such as viral resistance and treatment failure, as well as vaccines and future therapies for viral hepatitis and NASH.

Without independent conferences like HEP DART, scientists and physicians would not have the opportunity to network with each other and communicate new information on novel regimens in productive and high-quality events.

Meeting objectives

This meeting aims to:
- Review current treatment guidelines for HCV in adults and children
- Increase awareness of the clinical impact of antiviral agents
- Provide an independent platform for scientific exchange and networking

Learning objectives

After attending this meeting, participants will be able to:
- Describe the role of viral targets in the drug development and discovery process
- Identify the next generation of inhibitors of viral hepatitis, NASH and HCC
- Describe the latest developments in HCV and HBV therapeutics
- Assess the impact of resistance and treatment failure in the drug development and discovery process
- Summarize the role of hepatic cells in viral pathogenesis
- Understand immune status and the viral genetics of viral hepatitis
- Identify the consequences of NASH and co-infections with HIV on the management of patients
- Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis, NASH, and co-infections with HIV
- Understand the transmission of viral hepatitis
PROGRAM DESCRIPTION

The focus of HEP DART is to assemble clinicians, medical professionals, nurses, researchers and basic scientists together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis, NASH, and co-infections. HEP DART 2019 will blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in hepatology (including viral hepatitis, NASH, and co-infections).

Topics from Previous Editions
The program for HEP DART 2019 is still being developed, but below are some of the topics covered in the 2017 edition:

Eliminating Hepatitis B & C; Global strategies
Access to HIV, HBV, and HCV antiviral agents globally
DAA Therapy
Immunology of HBV
Hepatitis B/C and NASH
Resistance, Cell Biology and Other Hepatitis Viruses
Emerging therapeutic targets and concepts for Delta Hepatitis Virus
Clinical challenges in HCV infection
NASH globally: pathways to combination therapy, Biomarkers and outcomes
Management of HCV in decompensated liver disease
The effectiveness of treatment for chronic Hepatitis C (and hepatitis B) in pediatric populations
Regulatory landscape for NASH

HEP DART Award History

The William H. Prusoff
HEP DART Lifetime Achievement Award

Instituted in 2005, the William H. Prusoff HEP DART Lifetime Achievement Award is given at each HEP DART conference to a researcher who has made integral contributions over their career toward the advancement of care of persons infected with hepatitis viruses.

2005 Jesse Summers, University of New Mexico, USA
2007 Harvey Alter, National Institutes of Health, USA
2009 Michael Houghton, Epiphany Biosciences Inc.
2011 Robert Purcell, NIAID, NIH, USA
2013 Stephen Feinstone, Adjunct Professor Department of Biochemistry and Molecular Medicine, George Washington University School of Medicine and Health Sciences, USA
2015 Francis Chisari, Emeritus Professor of Virology and Immunology at The Scripps Research Institute, USA
2017 John Martin, Chairman and Former CEO, Gilead Sciences, USA
INFECTIOUS DISEASES ONLINE

Enduring information presented at the conference will be freely accessible and widely disseminated to reach thousands of virtual participants beyond the walls of the conference center. Infectious Diseases Online is a premier online platform offering scientific materials in special topical areas and proceedings of conferences. All the content on Infectious Diseases Online is organized by workshop and date, making it easy to find.

Visitors of the website will have full access to:
- Abstract Books
- Meeting Reports
- Workshop Presentations
- Webcasts
LEARNING ASSESSMENT METHOD

To assess the meeting, Virology Education provides each delegate with a detailed feedback form to assess the speakers, whether or not the meeting objectives were met, their intent to change, the rationale behind their motivation to attend, the general logistics of the meeting, and more.

All the questions are then fully analyzed and a comprehensive report is created and shared with the committee members. These reports help us to better understand our delegates’ needs and how to improve the meeting in the future.

For a maximum response rate, we invite the chairs of each session to encourage the participants to take a few minutes and complete the feedback forms. We are also introducing a web-based application to allow participants access to the feedback forms electronically.

Conference participation grants
The conference participation grants (CPG) provide healthcare professionals with the opportunity to attend a conference they would otherwise be unable to attend due to financial restrictions. All applications include a CV, a motivation letter, and potentially an abstract (requirements vary depending on the workshop). These are submitted via an independent CPG portal and are evaluated against the assessment criteria using a robust, impartial and independent peer review process. This process will ensure that the most qualified candidates will receive CPGs.

The grants are supported by the financial contributions allocated by the sponsor, who has no control, influence, or involvement in the selection process of the CPG candidates whatsoever. Priority is given to applicants who have actively participated in original research or scientific work that is being presented at the meeting and/or those who will profit most from participating in order to improve their daily clinical management.

These grants help defray costs for registration, travel and accommodation for delegates and foster their ability to form valuable professional networks and develop vital collaborations. Conference participation grant applications will be solicited, selected and awarded by an expert Grant Review Committee.

Accreditation
We aim to submit an application to the Emory University School of Medicine CME® for CME accreditation of this event.
SUPPORT

HEP DART 2017 WAS SPONSORED BY

PREMIER LEVEL

abbbvie

GOLD LEVEL

Arbutus Biopharma
Gilead
Janssen
RES & Family Foundation
Emory University
Center for AIDS Research
W.H. Prusoff Foundation

SILVER LEVEL

正大天晴药业集团

BRONZE LEVEL

THE BLATT FAMILY FOUNDATION
Galmed Pharmaceuticals
Hepatitis B Foundation

CONTRIBUTORS

arrowhead Pharmaceuticals
Contravir
ST PHARM
SPONSOR BENEFITS

As a sponsor of HEP DART, you will have the unique opportunity to connect with clinicians and researchers from academia, research institutes and governments. Engage with potential collaborators and experts and discuss the latest advancements and information in the field of hepatitis.

Sponsoring this program will give you the following benefits:

Visibility
- Prominent placement of your logo on conference materials (online and offline)
- Pre-event marketing and branding through:
  - Banners posted on the homepage of the website
  - Traffic generation to your website via the conference website
  - Your logo placed on monthly newsletters which are delivered to thousands of opt-in subscribers
  - Electronic advertising posted on several calendars linked to the event website

Contribution to the program
- A chance to organize satellite symposia
- Participate in discussions

Commercial benefits
- Exhibition opportunities
- Promotion option to display marketing materials such as pamphlets, flyers, postcards and other materials on the marketing table (subject to approval)

Privileges
Your contribution entitles you to the following privileges:
- Exhibition space
- Symposia inclusion
- Complimentary registrations to the event to increase your networking opportunities
- Other benefits described under various sponsorship levels

We will be more than willing to discuss these opportunities with you
With over 20 years of experience, Virology Education is a leading provider of innovative scientific and educational programs worldwide. Our programs provide excellent platforms for scientific exchange, education and knowledge-sharing tailored to the needs of healthcare professionals in the fields of infectious diseases, pharmacology, liver disease, and more. Our activities include the initiation and organization of real-time and online platforms for international exchange, knowledge-sharing and education for medical professionals. We have developed long-standing collaborations with world-leading experts and work together with other important stakeholders to achieve the greatest impact for our programs and to provide top quality scientific content. Our programs range from international abstract-driven workshops to small and large scale educational series, masterclasses, advisory boards, expert rounds, satellite symposia, and more.

Biltstraat 106
3572 BJ Utrecht
The Netherlands
www.virology-education.com
info@virology-education.com
+31 30 230 7146

Nicole Parise
Project Manager
nicole@vironet.com

Wilco Keulen, PhD
Senior Scientist
wilco@vironet.com

Maryam Ehteshami
Medical Consultant
maryam@vironet.com

More than 50 programs are planned for 2018 in more than 30 different cities around the globe!

OUR IMPACT IN 2017

46 programs | 4,187 participants | 2,277 accepted abstracts
59% returning participants | 28,000+ opt in subscribers